Top 50 corporate institutions in biomedical sciences
The table shows leading corporate institutions ranked by their fractional count (FC) in biomedical sciences from 2015 to 2018. Also listed are institution's total number of biomedical science articles in the Nature Index (AC 2015–2018) and the proportion of each institution's FC in biomedical sciences relative to total FC from 2015 to 2018 (biomedical sciences %).
* Click on column headers to sort
1 | F. Hoffmann-La Roche AG | Switzerland | 156.84 | 358 | 78.7 % |
2 | Novartis International AG | Switzerland | 104.69 | 268 | 80.5 % |
3 | AstraZeneca plc | United Kingdom (UK) | 71.26 | 218 | 67.1 % |
4 | Pfizer Inc. | United States of America (USA) | 52.53 | 157 | 57.5 % |
5 | GlaxoSmithKline plc. (GSK) | United Kingdom (UK) | 52.43 | 191 | 69.7 % |
6 | Amgen Inc. | United States of America (USA) | 51.27 | 153 | 75.3 % |
7 | Merck & Co., Inc. | United States of America (USA) | 41.03 | 121 | 35.9 % |
8 | BGI | China | 29.62 | 134 | 95.5 % |
9 | Johnson & Johnson | United States of America (USA) | 22.86 | 94 | 64.7 % |
10 | Eli Lilly and Company | United States of America (USA) | 22.57 | 78 | 64.1 % |
11 | Formosa Plastics Group | Taiwan | 22.18 | 88 | 76.6 % |
12 | Regeneron Pharmaceuticals, Inc. | United States of America (USA) | 20.68 | 52 | 94.4 % |
13 | Bristol-Myers Squibb (BMS) | United States of America (USA) | 19.56 | 74 | 39.0 % |
14 | Sanofi | France | 19.08 | 73 | 72.9 % |
15 | Ionis Pharmaceuticals, Inc. | United States of America (USA) | 15.41 | 73 | 93.1 % |
16 | Takeda Pharmaceutical Company Limited | Japan | 15.18 | 42 | 76.8 % |
17 | New England Biolabs, Inc. (NEB) | United States of America (USA) | 14.35 | 32 | 96.7 % |
18 | Alphabet Inc. | United States of America (USA) | 13.98 | 48 | 31.2 % |
19 | Biogen Inc. | United States of America (USA) | 13.60 | 60 | 91.8 % |
20 | Novo Nordisk A/S | Denmark | 13.37 | 44 | 78.1 % |
21 | AbbVie Inc. | United States of America (USA) | 13.23 | 39 | 64.3 % |
22 | Illumina, Inc. | United States of America (USA) | 12.15 | 73 | 93.4 % |
23 | IBM Corporation | United States of America (USA) | 12.02 | 46 | 6.3 % |
24 | C. H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim) | Germany | 9.01 | 35 | 30.5 % |
25 | Thermo Fisher Scientific Inc. | United States of America (USA) | 8.20 | 60 | 26.7 % |
26 | Bayer AG | Germany | 8.14 | 44 | 60.3 % |
27 | Human Longevity, Inc. | United States of America (USA) | 7.84 | 18 | 99.2 % |
28 | Merck KGaA | Germany | 7.60 | 30 | 47.4 % |
29 | Nestlé S.A. | Switzerland | 7.27 | 35 | 70.2 % |
30 | UCB S.A. | Belgium | 6.91 | 33 | 54.4 % |
31 | Gilead Sciences, Inc. | United States of America (USA) | 6.77 | 22 | 88.8 % |
32 | 23andMe, Inc. | United States of America (USA) | 5.74 | 50 | 92.0 % |
33 | H3 Biomedicine Inc. | United States of America (USA) | 5.63 | 15 | 100.0 % |
34 | Pacific Biosciences of California, Inc. | United States of America (USA) | 5.43 | 32 | 89.6 % |
35 | DowDuPont Inc. | United States of America (USA) | 5.38 | 23 | 10.7 % |
36 | Seattle Genetics, Inc. | United States of America (USA) | 5.03 | 6 | 71.5 % |
37 | Alnylam Pharmaceuticals, Inc. | United States of America (USA) | 4.98 | 15 | 100.0 % |
38 | Sosei Co., Ltd. | Japan | 4.96 | 8 | 97.8 % |
39 | Synthetic Genomics, Inc. (SGI) | United States of America (USA) | 4.70 | 7 | 100.0 % |
40 | Celgene Corporation | United States of America (USA) | 4.57 | 15 | 100.0 % |
41 | Momenta Pharmaceuticals, Inc. | United States of America (USA) | 4.40 | 7 | 100.0 % |
42 | GeneDx | United States of America (USA) | 4.29 | 54 | 100.0 % |
43 | Constellation Pharmaceuticals | United States of America (USA) | 4.19 | 9 | 100.0 % |
44 | Sangamo Therapeutics Inc. | United States of America (USA) | 4.14 | 10 | 100.0 % |
45 | Daiichi Sankyo Co., Ltd. | Japan | 4.04 | 26 | 67.6 % |
46 | Nippon Telegraph and Telephone Corporation (NTT) | Japan | 4.01 | 8 | 6.7 % |
47 | BASF SE | Germany | 4.00 | 15 | 12.4 % |
48 | Genmab B.V. | Netherlands | 3.89 | 8 | 94.0 % |
49 | Shimadzu Corporation | Japan | 3.88 | 13 | 46.8 % |
50 | Austrian Centre of Industrial Biotechnology (ACIB) | Austria | 3.84 | 15 | 51.5 % |